Evidence map›Paper›PMID 32532255›Full record

SynthesisJournal of translational medicine2020

Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Yue An, Zhonghua Wu, Ningning Wang, Zhidong Yang, Yue Li, Boyang Xu, Mingjun Sun

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 5 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 5 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yue AnDepartment of Gastroenterology, The First Hospital of China Medical University, 155 Nanjing bei Road, Shenyang, Liaoning, 110001, People's Republic of China.
Zhonghua WuDepartment of Surgical Oncology and General Surgery, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
Ningning WangDepartment of Gastroenterology, The First Hospital of China Medical University, 155 Nanjing bei Road, Shenyang, Liaoning, 110001, People's Republic of China.
Zhidong YangDepartment of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, People's Republic of China.
Yue LiDepartment of Gastroenterology, The First Hospital of China Medical University, 155 Nanjing bei Road, Shenyang, Liaoning, 110001, People's Republic of China.
Boyang XuDepartment of Gastroenterology, The First Hospital of China Medical University, 155 Nanjing bei Road, Shenyang, Liaoning, 110001, People's Republic of China.
Mingjun SunDepartment of Gastroenterology, The First Hospital of China Medical University, 155 Nanjing bei Road, Shenyang, Liaoning, 110001, People's Republic of China. sunmjmw@163.com.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs efficacy. The purpose of our current meta-analysis was to clearly evaluated the relationship between BMI and ICIs efficacy for cancer patients receiving immunotherapy.

methodsA systematic search of Pubmed, EMBASE and conference proceedings was performed to investigate the influence of BMI on ICIs efficacy. Pooled analysis for overall survival (OS), progression-free survival (PFS) and immune-related adverse effects (IRAEs) were analyzed in current study.

resultsA total of 13 eligible studies comprising 5279 cancer patients treated with ICIs were included in the analysis. The pooled analysis showed there is positive association between high BMI and improved OS and PFS among patients with ICIs treatment (OS: HR = 0.62, 95% CI 0.55-0.71, P < 0.0001; I

conclusionAn improved OS and PFS were observed in patients with high BMI after receiving ICIs treatment compared with patients of low BMI. No significant association between BMI and incidence of IRAEs was found in cancer patients after ICIs treatment.

Indexed as

Drug-Related Side Effects and Adverse ReactionsNeoplasmsBody Mass IndexHumansImmune Checkpoint InhibitorsImmunotherapyImmune Checkpoint InhibitorsBody mass indexImmune checkpoint inhibitorsOverall survivalProgression-free survival

Identifiers

PMID32532255
PMCPMC7291531
OpenAlexW3034348710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.